Dual checkpoint inhibitor

This page covers all Dual checkpoint inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1 and CTLA-4.

Targets

PD-1 and CTLA-4

Phase 3 pipeline (1)

• APVO101 · Medexus Pharma, Inc. · Oncology
  APVO101 is a dual checkpoint inhibitor that blocks both PD-1 and CTLA-4 pathways to enhance anti-tumor immune responses.